| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8580703 | Primary Care Diabetes | 2018 | 8 Pages |
Abstract
We performed a PRISMA systematic review of incretin-based therapies and effects on neurocognitive function in humans. There was observational evidence to support dipeptidyl peptidase-IV inhibitors in improving cognition, whilst glucagon-like peptide-1 had positive effects on cerebral glucose metabolism. Powered clinical trials are now needed in patients with- and without diabetes.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Jonathan L. Dumbrill, Calum D. Moulton,